04:25 PM EDT, 07/02/2024 (MT Newswires) -- Gyre Therapeutics ( GYRE ) said Tuesday it has received approval in China for avatrombopag maleate tablets for the treatment of low blood platelet count associated with chronic liver disease.
The drug is approved for adult patients undergoing elective diagnostic procedures or therapy.
Gyre Therapeutics' ( GYRE ) unit Gyre Pharmaceuticals acquired avatrombopag from Nanjing Healthnice Pharmaceutical Technology in June 2021.